Version 1
: Received: 20 January 2024 / Approved: 22 January 2024 / Online: 22 January 2024 (14:08:41 CET)
How to cite:
Magnelli, V. Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's Disease. Preprints2024, 2024011595. https://doi.org/10.20944/preprints202401.1595.v1
Magnelli, V. Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's Disease. Preprints 2024, 2024011595. https://doi.org/10.20944/preprints202401.1595.v1
Magnelli, V. Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's Disease. Preprints2024, 2024011595. https://doi.org/10.20944/preprints202401.1595.v1
APA Style
Magnelli, V. (2024). Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's Disease. Preprints. https://doi.org/10.20944/preprints202401.1595.v1
Chicago/Turabian Style
Magnelli, V. 2024 "Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's Disease" Preprints. https://doi.org/10.20944/preprints202401.1595.v1
Abstract
Alzheimer’s disease (AD) is one of the most widespread neurodegenerative diseases affecting people averaging over 65 years. It manifests with severe cognitive damage, loss of memory, impairment in performing activities, ventricular expansion and final dementia. AD is associated with the deposit of amyloid β protein (Aβ) plaques, intracellular neurofibrillary tangles (NFTs), progressive inflammation and impairment of synaptic transmission and of mitochondrial function. Due to the poor diagnostic tools for the early stages of the disease, proteomics biomarkers have gained a paramount role because they can monitor the prodromal variations of the disease-linked molecular changes. Further, proteome biomarkers can help the follow up of AD progression over time and aid in setting personalized medical care, before the catastrophic consequences of dementia occurs. Research has focused on the identification of proteome biomarkers in cerebrospinal fluid (CSF) and plasma, which are discussed in the present review, but also in other matrices, as saliva and urine, revealing the high potentiality of proteomics approach and, at the same time, the difficulty to identify, for the different stages of the disease, sensitive and specific biomarkers clinically available.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
